The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 28324649 |
99 |
Sulfonamides as Selective Na |
Amgen |
| 28287723 |
73 |
Sulfonamides as Selective Na |
Amgen |
| 28234467 |
108 |
Development of New Benzenesulfonamides As Potent and Selective Na |
Bristol-Myers Squibb |
| 28337315 |
22 |
Sodium Channel Blockers. |
Temple University |
| 28337316 |
16 |
Bicyclic Ketone Sulfonamide Compounds. |
Temple University |
| 27994738 |
50 |
Sulfonamides as Selective Na |
Amgen |
| 26985315 |
49 |
Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models. |
Xenon Pharmaceuticals |
| 26890998 |
572 |
Single Residue Substitutions That Confer Voltage-Gated Sodium Ion Channel Subtype Selectivity in the NaV1.7 Inhibitory Peptide GpTx-1. |
Amgen |
| 26713098 |
14 |
Sulfonamide Compounds as Voltage Gated Sodium Channel Modulators. |
Temple University |
| 26396679 |
6 |
Nav1.7 Inhibitors: Potential Effective Therapy for the Treatment of Chronic Pain. |
Therachem Research Medilab (India) |
| 26358159 |
114 |
Discovery of (phenoxy-2-hydroxypropyl)piperidines as a novel class of voltage-gated sodium channel 1.7 inhibitors. |
Daiichi Sankyo |
| 25927480 |
36 |
Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications. |
Merck Research Laboratories |
| 25288187 |
45 |
Bioavailable pyrrolo-benzo-1,4-diazines as Na(v)1.7 sodium channel blockers for the treatment of pain. |
Merck Research Laboratory |
| 26101568 |
51 |
Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain. |
Pfizer |
| 25466191 |
17 |
Dibenzazepines and dibenzoxazepines as sodium channel blockers. |
Purdue Pharma |
| 25435147 |
24 |
N-Aryl azacycles as novel sodium channel blockers. |
Purdue Pharma |
| 25658507 |
218 |
Engineering potent and selective analogues of GpTx-1, a tarantula venom peptide antagonist of the Na(V)1.7 sodium channel. |
Amgen |
| 25113934 |
65 |
Discovery of pyrrolo-benzo-1,4-diazines as potent Na(v)1.7 sodium channel blockers. |
Merck Research Laboratory |
| 25026046 |
42 |
Studies examining the relationship between the chemical structure of protoxin II and its activity on voltage gated sodium channels. |
Purdue Pharma |
| 25176194 |
69 |
The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7. |
Xenon Pharmaceuticals |
| 24601592 |
48 |
Imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis. |
University College London |
| 23121096 |
86 |
Ion channels as therapeutic targets: a drug discovery perspective. |
Pfizer |
| 21641215 |
55 |
Phenyl isoxazole voltage-gated sodium channel blockers: structure and activity relationship. |
Astrazeneca |
| 22770500 |
219 |
3-Oxoisoindoline-1-carboxamides: potent, state-dependent blockers of voltage-gated sodium channel Na(V)1.7 with efficacy in rat pain models. |
Astrazeneca |
| 24900534 |
6 |
Cyclopropyl-spiro-piperidines Useful as Sodium Channel Blockers: Patent Highlight. |
TBA |
| 24900533 |
22 |
Substituted pyridines as sodium channel blockers: patent highlight. |
TBA |
| 22939696 |
85 |
Phenethyl nicotinamides, a novel class of Na(V)1.7 channel blockers: structure and activity relationship. |
Astrazeneca |
| 22832315 |
85 |
Structure and activity relationship in the (S)-N-chroman-3-ylcarboxamide series of voltage-gated sodium channel blockers. |
Astrazeneca |
| 22318156 |
128 |
Discovery and hit-to-lead optimization of pyrrolopyrimidines as potent, state-dependent Na(v)1.7 antagonists. |
Amgen |
| 22306122 |
90 |
The discovery of aminopyrazines as novel, potent Na(v)1.7 antagonists: hit-to-lead identification and SAR. |
Amgen |
| 17483457 |
58 |
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. |
Abbott Laboratories |
| 18243692 |
85 |
Imidazopyridines: a novel class of hNav1.7 channel blockers. |
Merck Research Laboratories |
| 22364743 |
8 |
Asymmetric synthesis and evaluation of a hydroxyphenylamide voltage-gated sodium channel blocker in human prostate cancer xenografts. |
University of Virginia |
| 22209205 |
38 |
Discovery and optimization of aminopyrimidinones as potent and state-dependent Nav1.7 antagonists. |
Amgen |
| 21634377 |
73 |
Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain. |
Amgen |
| 21570288 |
57 |
Discovery of XEN907, a spirooxindole blocker of NaV1.7 for the treatment of pain. |
Xenon Pharmaceuticals |
| 21106456 |
35 |
Discovery of a novel class of biphenyl pyrazole sodium channel blockers for treatment of neuropathic pain. |
Merck Research Laboratories |
| 20709552 |
36 |
Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers. |
Merck Research Laboratories |
| 20709545 |
31 |
Substituted biaryl pyrazoles as sodium channel blockers. |
Merck Research Laboratories |
| 20394379 |
2 |
Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities. |
University of North Carolina |
| 19683443 |
26 |
Discovery of isoxazole voltage gated sodium channel blockers for treatment of chronic pain. |
Merck Research Laboratories |
| 19674896 |
12 |
Discovery of a novel class of isoxazoline voltage gated sodium channel blockers. |
Merck Research Laboratories |
| 18289851 |
24 |
3-Amino-1,5-benzodiazepinones: potent, state-dependent sodium channel blockers with anti-epileptic activity. |
Merck Research Laboratories |
| 17889534 |
24 |
Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain. |
Merck Research Laboratories |
| 17588748 |
46 |
Discovery of a novel class of benzazepinone Na(v)1.7 blockers: potential treatments for neuropathic pain. |
Merck Research Laboratories |
| 17489575 |
7 |
Sodium channel blockers. |
Purdue Pharma |
| 16337121 |
22 |
Synthesis and SAR of 1,2-trans-(1-hydroxy-3-phenylprop-1-yl)cyclopentane carboxamide derivatives, a new class of sodium channel blockers. |
Merck Research Laboratories |
| 15878274 |
33 |
Discovery of potent and use-dependent sodium channel blockers for treatment of chronic pain. |
Merck Research Laboratories |
| 15780630 |
74 |
Novel cyclopentane dicarboxamide sodium channel blockers as a potential treatment for chronic pain. |
Merck Research Laboratories |
| 32368909 |
99 |
Discovery of Potent, Selective, and State-Dependent Na |
Lupin |
| 32787109 |
45 |
Exploration of TRPM8 Binding Sites by ?-Carboline-Based Antagonists and Their In Vitro Characterization and In Vivo Analgesic Activities. |
University of Salerno |
| 32392056 |
108 |
Discovery of DS-1971a, a Potent, Selective Na |
Daiichi Sankyo |
| 27441383 |
117 |
Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors. |
Amgen |
| 31531190 |
10 |
Sodium Channel Modulators and Their Method of Use. |
Temple University |
| 30943032 |
31 |
Structure- and Ligand-Based Discovery of Chromane Arylsulfonamide Na |
Genentech |
| 30576602 |
157 |
Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective Na |
Bristol-Myers Squibb Research and Development |
| 30638874 |
64 |
Discovery of new indole-based acylsulfonamide Na |
Bristol-Myers Squibb Research and Development |
| 30538065 |
48 |
The discovery and optimization of benzimidazoles as selective Na |
Pfizer |
| 27015369 |
78 |
Substituted Indazoles as Nav1.7 Blockers for the Treatment of Pain. |
Abbvie |
| 25060923 |
44 |
Recent progress in sodium channel modulators for pain. |
Pfizer |
| 24440379 |
179 |
Substituted 4-phenyl-2-aminoimidazoles and 4-phenyl-4,5-dihydro-2-aminoimidazoles as voltage-gated sodium channel modulators. |
University of Ljubljana |
| 24148992 |
60 |
Novel state-dependent voltage-gated sodium channel modulators, based on marine alkaloids from Agelas sponges. |
University of Ljubljana |
| 23652221 |
23 |
A novel benzazepinone sodium channel blocker with oral efficacy in a rat model of neuropathic pain. |
Merck Research Laboratories |
| 23177785 |
1017 |
QSAR investigation of NaV1.7 active compounds using the SVM/Signature approach and the Bioclipse Modeling platform. |
Astrazeneca |
| 30139550 |
11 |
Na |
Genentech |
| 29737846 |
70 |
Design of Conformationally Constrained Acyl Sulfonamide Isosteres: Identification of N-([1,2,4]Triazolo[4,3- a]pyridin-3-yl)methane-sulfonamides as Potent and Selective hNa |
Xenon Pharmaceuticals |
| 29541350 |
24 |
Acyl Sulfonamides NaV1.7 Blockers Useful for the Treatment of Pain. |
Temple University |
| 28988749 |
7 |
Peptide therapeutics from venom: Current status and potential. |
Peptides International |
| 29439904 |
91 |
Discovery of morpholine-based aryl sulfonamides as Na |
Bristol-Myers Squibb Research and Development |
| 29116786 |
265 |
Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies. |
Idorsia Pharmaceuticals |
| 29037948 |
70 |
Discovery of aminocyclohexene analogues as selective and orally bioavailable hNav1.7 inhibitors for analgesia. |
Wuxi Apptec (Shanghai) |
| 29029933 |
45 |
Highly potent and selective Na |
Pfizer |
| 30346167 |
71 |
Discovery of Tarantula Venom-Derived Na |
Amgen |
| 29709252 |
31 |
1,2,4-Triazolsulfone: A novel isosteric replacement of acylsulfonamides in the context of Na |
Amgen |
| 28684121 |
60 |
Discovery of a biarylamide series of potent, state-dependent Na |
Amgen |
| 28629594 |
55 |
The discovery of benzoxazine sulfonamide inhibitors of Na |
Amgen |
| 28818462 |
157 |
Discovery of non-zwitterionic aryl sulfonamides as Na |
Bristol-Myers Squibb Research and Development |
| 28682065 |
133 |
Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of Na |
Icagen |
| 28626530 |
71 |
Discovery of a Series of Indazole TRPA1 Antagonists. |
Pfizer |
| 28465103 |
22 |
Benzoxazolinone aryl sulfonamides as potent, selective Na |
Merck |
| 28389149 |
56 |
Discovery of selective, orally bioavailable, N-linked arylsulfonamide Na |
Department of Discovery Chemistry Merck |
| 28385504 |
52 |
The discovery of tetrahydropyridine analogs as hNav1.7 selective inhibitors for analgesia. |
Wuxi Apptec (Shanghai) |
| 11459929 |
7 |
Trace amines: identification of a family of mammalian G protein-coupled receptors. |
Synaptic Pharmaceutical |
| 16206825 |
3 |
6-(N-benzoylamino)purine as a novel and potent inhibitor of xanthine oxidase: inhibition mechanism and molecular modeling studies. |
National Institute of Pharmaceutical Education and Research |
| 8884876 |
47 |
Characterisation of the melanocortin 4 receptor by radioligand binding. |
Uppsala University |
| 19396178 |
6 |
Impact of linker strain and flexibility in the design of a fragment-based inhibitor. |
Johns Hopkins University |
| 19338333 |
37 |
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis. |
Kochi Medical School |
| 19138845 |
44 |
Parallel medicinal chemistry approaches to selective HDAC1/HDAC2 inhibitor (SHI-1:2) optimization. |
Merck Research Laboratories |
| 19093884 |
36 |
Non-peptide macrocyclic histone deacetylase inhibitors. |
Georgia Institute of Technology |
| 18374572 |
100 |
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct. |
Universita Degli Studi Di Firenze |
| 15743201 |
58 |
Structure-based design, synthesis, and study of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III as potential antimicrobial agents. |
Quorex Pharmaceuticals |
| 17556356 |
4 |
Crystal structure of human estrogen-related receptor alpha in complex with a synthetic inverse agonist reveals its novel molecular mechanism. |
Novartis |
| 16509583 |
114 |
Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases. |
University of Alberta |
| 17034120 |
4 |
Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. |
Eli Lilly |
| 15664855 |
19 |
Non-peptidic small molecule inhibitors of XIAP. |
Abbott Laboratories |
| 16884309 |
5 |
Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor. |
Taigen Biotechnology |
| 8360874 |
19 |
Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligands. |
Merck Research Laboratories |
| 12039591 |
63 |
Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck - a selectivity insight. |
Abbott Bioresearch Center |
| 16298527 |
10 |
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains. |
University of Pennsylvania |
| 15993068 |
101 |
2-Aminoquinazoline inhibitors of cyclin-dependent kinases. |
Naeja Pharmaceutical |
| 8423600 |
13 |
3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors. |
Merck Research Laboratories |
| 11112523 |
7 |
Estimation of the hydrophobic effect in an antigen-antibody protein-protein interface. |
University of Maryland Biotechnology Institute |
Search and Browse
